Inhibition of YAP activation attenuates renal injury and fibrosis in angiotensin II hypertensive mice
Authors:
- 1 October 2021
- journal article
- research article
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 99 (10) , 1000-1006
Abstract
The Hippo/YAP (yes-associated protein) pathway is an important signaling pathway to control organ development and tissue homeostasis. YAP is a downstream effector of the Hippo pathway and a critical mediator of mechanic stress. Hypertensive nephropathy is characterized with glomerular sclerosis stiffness and renal fibrosis. The present study investigated the role of YAP pathway in angiotensin (Ang) II hypertensive renal injury by using YAP activation inhibitor verteporfin. Ang II increased the protein expression of YAP in renal nucleus fraction, decreased phospho-YAP, and phospho-LATS1/2 (large tumor suppressors 1 and 2) expressions in renal cytoplasmic fraction, suggesting Ang II activation of renal YAP. Ang II significantly increased systolic blood pressure (SBP), proteinuria, glomerular sclerosis, and fibrosis; treatment with verteporfin attenuated Ang II–induced proteinuria and renal injury with a mild reduction in SBP. Moreover, Ang II increased the protein expressions of inflammatory factors including tumor necrosis factor α, interleukin 1β, and monocyte chemoattractant protein-1, and profibrotic factors including transforming growth factor β, phospho-Smad3 and fibronectin. Verteporfin reversed abovementioned Ang II–induced molecule expressions. Our results for the first time demonstrate that the activation of the YAP pathway promotes hypertensive renal inflammation and fibrosis, which may promote hypertensive renal injury. YAP may be a new target for prevention and treatment of hypertensive renal diseases.Keywords
This publication has 33 references indexed in Scilit:
- YAP/TAZ Are Mechanoregulators of TGF-β-Smad Signaling and Renal FibrogenesisJournal of the American Society of Nephrology, 2016
- Involvement of the Hippo pathway in regeneration and fibrogenesis after ischaemic acute kidney injury: YAP is the key effectorClinical Science, 2016
- Interaction of the EGF Receptor and the Hippo Pathway in the Diabetic KidneyJournal of the American Society of Nephrology, 2015
- Glomerular Density in Biopsy-Proven Hypertensive NephrosclerosisAmerican Journal of Hypertension, 2015
- The Hippo pathway is controlled by Angiotensin II signaling and its reactivation induces apoptosis in podocytesCell Death & Disease, 2014
- The Biology of YAP/TAZ: Hippo Signaling and BeyondPhysiological Reviews, 2014
- Role of extracellular matrix and YAP/TAZ in cell fate determinationCellular Signalling, 2014
- Disruption of Smad7 Promotes ANG II-Mediated Renal Inflammation and Fibrosis via Sp1-TGF-β/Smad3-NF.κB-Dependent Mechanisms in MicePLOS ONE, 2013
- Smad3 mediates ANG II-induced hypertensive kidney disease in miceAmerican Journal of Physiology-Renal Physiology, 2012
- Role of YAP/TAZ in mechanotransductionNature, 2011